Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7750327 | 1.00 | PLK1 (0.41) | PLK1KDM4EPOLBALDH1A1MEN1 | |
| Acetic Acid SCHEMBL917018 | 0.91 | PLK1 (0.41) | PLK1KDM4EPOLBALDH1A1MEN1 | |
| Acetic Acid SCHEMBL917020 | 0.91 | PLK1 (0.41) | PLK1KDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL19449722 | 0.85 | PLK1 (0.43) | PLK1KDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL18131646 | 0.84 | POLB (0.40) | KDM4EPOLBMEN1LMNAMAPT | |
| SCHEMBL18130862 | 0.84 | POLB (0.40) | KDM4EPOLBMEN1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL17560860 | 0.83 | PLK1 (0.42) | PLK1KDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL7748673 | 0.83 | GRIN2D (0.55) | KDM4EPOLBALDH1A1LMNAMAPT | |
| SCHEMBL7748676 | 0.83 | GRIN2D (0.55) | KDM4EPOLBALDH1A1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL5703045 | 0.82 | GRIN2D (0.56) | KDM4EPOLBALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111896-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2018-04-26 | — | — | US | claimed |
| EP-3280405-A1 | INHIBITORS AND THEIR USES | Medical Research Council (GB) | 2018-02-14 | — | — | EP | claimed |
| WO-2016162689-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2016-10-13 | — | — | WO | claimed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | claimed |
| US-11337941-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-05-24 | — | — | US | disclosed |
| US-11337941-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-05-24 | — | — | US | disclosed |
| US-11331286-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-05-17 | — | — | US | disclosed |
| US-11331286-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-05-17 | — | — | US | disclosed |
| US-11154519-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2021-10-26 | — | — | US | disclosed |
| US-11154519-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2021-10-26 | — | — | US | disclosed |
| EP-3280405-B1 | INHIBITORS AND THEIR USES | RES & INNOVATION UK (GB) | 2021-07-07 | — | — | EP | disclosed |
| EP-3280405-B1 | INHIBITORS AND THEIR USES | RES & INNOVATION UK (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
| US-20180111896-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2018-04-26 | — | — | US | disclosed |
| US-20180111896-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2018-04-26 | — | — | US | disclosed |
| US-20180111896-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2018-04-26 | — | — | US | disclosed |
| EP-3280405-A1 | INHIBITORS AND THEIR USES | Medical Research Council (GB) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016162689-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016162689-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2016-10-13 | — | — | WO | disclosed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111896-A1 | INHIBITORS AND THEIR USES | PPP1R1B, PPP5C, PPP1R15A | PLK1 1652/4885KDM4E 1965/4885POLB 3558/4885 |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | OPRL1, INA, OGFR | PLK1 4577/4885KDM4E 2078/4885POLB 4376/4885 |
| US-11154519-B2 | Inhibitors and their uses | PPP1R1B, PPP5C, PPP1R15A | PLK1 1652/4885KDM4E 1965/4885POLB 3558/4885 |
| US-11331286-B2 | Inhibitors and their uses | PPP1R1B, PPP5C, PPP1R15A | PLK1 1652/4885KDM4E 1965/4885POLB 3558/4885 |
| US-11337941-B2 | Inhibitors and their uses | PPP1R1B, PPP5C, PPP1R15A | PLK1 1652/4885KDM4E 1965/4885POLB 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.